The Focus of the Study is to Investigate the Effects of Phosphatidylserine Supplementation on Exercise Physiology and Cycling Time-trial Performance
Conditions
Brief summary
Phosphatidylserine is a phospholipid found in high concentrations in the brain and nervous tissues along with naturally occurring in many foods. It has been extensively studied for its effects on improving cognitive function, learning, memory and alleviating stress. However, more recently it has been proposed that phosphatidylserine could improve exercise capacity. The mechanisms of proposed action are difficult to distinguish because of the limited research and therefore the purpose of this study is to identify the proposed mechanism of action of phosphatidylserine supplementation and to establish whether these mechanisms will have an effect on time trial performance in trained male cyclists.
Interventions
DIETARY_SUPPLEMENTPhosphatidylserine
800 mg per day for 10 days
Sponsors
Mark Glaister
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
The experiment will follow a double-blind design where all participants and investigators will be blinded to the treatments given.
Intervention model description
Participants matched on cycling time-trial performance and then randomly assigned to treatment or placebo groups
Eligibility
Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Cyclists * Maximum oxygen uptake of at least 55 mL/kg/min
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 30 minute cycling time-trial power output on an electromagnetically-braked cycle ergometer | From baseline to 11 days post supplementation | Mean power output |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Respiratory exchange ratio at four different exercise intensities (40, 50, 60 and 70% percent of maximal oxygen uptake) on an electromagnetically-braked cycle ergometer | From baseline to 11 days post supplementation | Evaluated using an online breath-by-breath gas analyser |
| Breathing frequency at four different exercise intensities (40, 50, 60 and 70% percent of maximal oxygen uptake) on an electromagnetically-braked cycle ergometer | From baseline to 11 days post supplementation | Evaluated using an online breath-by-breath gas analyser |
| Minute ventilation at four different exercise intensities (40, 50, 60 and 70% percent of maximal oxygen uptake) on an electromagnetically-braked cycle ergometer | From baseline to 11 days post supplementation | Evaluated using an online breath-by-breath gas analyser |
| Oxygen consumption at four different exercise intensities (40, 50, 60 and 70% percent of maximal oxygen uptake) on an electromagnetically-braked cycle ergometer | From baseline to 11 days post supplementation | Evaluated using an online breath-by-breath gas analyser |
| Blood glucose concentration at four different exercise intensities (40, 50, 60 and 70% percent of maximal oxygen uptake) on an electromagnetically-braked cycle ergometer | From baseline to 11 days post supplementation | Obtained via capillary puncture and analysed using an automated analyser |
| Rating of perceived exertion at four different exercise intensities (40, 50, 60 and 70% percent of maximal oxygen uptake) on an electromagnetically-braked cycle ergometer | From baseline to 11 days post supplementation | Evaluated using a 15-point (6-20) scale |
| Heart rate at four different exercise intensities (40, 50, 60 and 70% percent of maximal oxygen uptake) on an electromagnetically-braked cycle ergometer | From baseline to 11 days post supplementation | Evaluated using a heart rate monitor |
| Blood lactate concentration at four different exercise intensities (40, 50, 60 and 70% percent of maximal oxygen uptake) on an electromagnetically-braked cycle ergometer | From baseline to 11 days post supplementation | Obtained via capillary puncture and analysed using an automated analyser |
Contacts
Primary ContactMark Glaister, PhD
Outcome results
None listed